Staidson (Beijing) BioPharmaceuticals Co., Ltd. (SHE:300204)
China flag China · Delayed Price · Currency is CNY
16.15
-0.34 (-2.06%)
Nov 17, 2026, 3:04 PM CST

SHE:300204 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
186.83220.19324.75364.04548.99584.28
Other Revenue
0.040.040.070.13-0.01
186.88220.23324.82364.18548.99584.29
Revenue Growth
-23.53%-32.20%-10.81%-33.66%-6.04%37.41%
Cost of Revenue
51.4550.2962.2774.6101.77116.43
Gross Profit
135.43169.95262.55289.57447.22467.86
Selling, General & Admin
157.52164.49195.91248.23310.77336.76
Research & Development
67.1284.94107.11412.26362.81362.51
Other Operating Expenses
4.43.754.084.436.727.82
Operating Expenses
228.45253.13306.86663.44681.08707.37
Operating Income
-93.02-83.18-44.31-373.86-233.87-239.51
Interest Expense
-14.53-8.49-0.64-1.17-0.36-0.65
Interest & Investment Income
2.040.970.632.657.3222.19
Currency Exchange Gain (Loss)
-0.26-0.260.2400-0
Other Non Operating Income (Expenses)
-0.27-0.15-0.210.02-0.241.46
EBT Excluding Unusual Items
-106.06-91.11-44.3-372.36-227.14-216.51
Impairment of Goodwill
-----2.42-
Gain (Loss) on Sale of Investments
0.23---0-1.460.21
Gain (Loss) on Sale of Assets
-0.220.640.20.3-0.04-
Asset Writedown
-2.74-1.83--2.34-21.71-0.09
Other Unusual Items
2.753.979.797.969.693.42
Pretax Income
-106.04-88.32-34.32-366.45-243.07-212.96
Income Tax Expense
-0.3-0.22113.4232.44-46.06-75.56
Earnings From Continuing Operations
-105.75-88.11-147.73-398.89-197.01-137.4
Minority Interest in Earnings
6.210.342.89---
Net Income
-99.54-77.76-144.84-398.89-197.01-137.4
Net Income to Common
-99.54-77.76-144.84-398.89-197.01-137.4
Net Income Growth
------
Shares Outstanding (Basic)
460486483475481474
Shares Outstanding (Diluted)
460486483475481474
Shares Change
-10.69%0.66%1.67%-1.17%1.42%-0.27%
EPS (Basic)
-0.22-0.16-0.30-0.84-0.41-0.29
EPS (Diluted)
-0.22-0.16-0.30-0.84-0.41-0.29
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Free Cash Flow
-189.41-202.31-87.21-260.47-232.12-218.31
Free Cash Flow Per Share
-0.41-0.42-0.18-0.55-0.48-0.46
Gross Margin
72.47%77.17%80.83%79.52%81.46%80.07%
Operating Margin
-49.78%-37.77%-13.64%-102.66%-42.60%-40.99%
Profit Margin
-53.27%-35.31%-44.59%-109.53%-35.89%-23.52%
Free Cash Flow Margin
-101.36%-91.86%-26.85%-71.52%-42.28%-37.36%
EBITDA
-68.83-59.62-21.58-342.43-202.38-205.42
EBITDA Margin
-36.83%-27.07%-6.64%-94.03%-36.86%-35.16%
D&A For EBITDA
24.1923.5722.7331.4431.4834.09
EBIT
-93.02-83.18-44.31-373.86-233.87-239.51
EBIT Margin
-49.78%-37.77%-13.64%-102.66%-42.60%-40.99%
Revenue as Reported
186.88220.23324.82364.18548.99584.29